Clinical Trials

Numerous clinical trials evaluate Brivanib across Phase 1, Phase 2, and Phase 3 studies for indications including advanced hepatocellular carcinoma, ovarian cancer, gastrointestinal malignancies, and cervical carcinoma. Sponsored by industry entities such as Bristol-Myers Squibb and Zai Lab alongside academic institutions like M.D. Anderson Cancer Center and Hunan Cancer Hospital, these investigations assess safety, pharmacokinetics, and therapeutic efficacy as monotherapy or combination regimens. Recruitment statuses across these studies range from completed and terminated to unknown, with significant emphasis placed on hepatocellular carcinoma populations.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04212221 TERMINATED
Advanced Hepatocellular Carcinoma (HCC)
Zai Lab (Shanghai) Co., Ltd.
 2020-04-20 PHASE1; PHASE2
NCT04395612 UNKNOWN
Cervical Cancer
Chongqing University Cancer Hospital
 2020-05-08 PHASE2
NCT03895788 UNKNOWN
Ovarian Cancer
Hunan Cancer Hospital
 2019-01-14 PHASE1
NCT03895788 Unknown status
Ovarian Cancer
Hunan Cancer Hospital
 2019-01-14 Phase 1
NCT03516071 COMPLETED
Hepatocellular Carcinoma (HCC)
Zai Lab (Shanghai) Co., Ltd.
 2017-05-17 PHASE2
NCT00888173 COMPLETED
Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Squamous Cell Carcinoma; Endometrial Transitional Cell Carcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma
Gynecologic Oncology Group
 2009-07-06 PHASE2
NCT00798252 COMPLETED
Advanced Cancer
Bristol-Myers Squibb
 2009-03 PHASE1
NCT01046864 COMPLETED
Gastro-Intestinal Cancer
Bristol-Myers Squibb
 2010-02 PHASE1
NCT01267253 COMPLETED
Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Persistent Disease; Recurrent Cervical Carcinoma
Gynecologic Oncology Group
 2011-04-04 PHASE2
NCT01367275 TERMINATED
Colorectal Cancer; Colorectal Adenocarcinoma
M.D. Anderson Cancer Center
 2011-08 PHASE2
NCT01540461 COMPLETED
Hepatocellular Carcinoma
Bristol-Myers Squibb
 2012-03 PHASE1
NCT01108705 TERMINATED
Carcinoma, Hepatocellular
Bristol-Myers Squibb
 2010-05 PHASE3
NCT01253668 TERMINATED
Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
 2011-11 PHASE2
NCT00594984 COMPLETED
Metastatic Colorectal Cancer (MCRC)
Bristol-Myers Squibb
 2008-05 PHASE1; PHASE2
NCT00908752 COMPLETED
Hepatocellular Carcinoma
Bristol-Myers Squibb
 2009-07-20 PHASE3
NCT00858871 COMPLETED
Hepato Cellular Carcinoma (HCC)
Bristol-Myers Squibb
 2009-05 PHASE3
NCT01540461 Completed
Hepatocellular Carcinoma
Bristol-Myers Squibb
 2012-03 Phase 1
NCT00633789 COMPLETED
Advanced Non-small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Bristol-Myers Squibb
 2008-06 PHASE2
NCT00825955 COMPLETED
Liver Cancer
Bristol-Myers Squibb
 2009-02-17 PHASE3
NCT00640471 COMPLETED
Colorectal Cancer
NCIC Clinical Trials Group
 2008-05-12 PHASE3
NCT00437424 COMPLETED
Carcinoma, Hepatocellular
Bristol-Myers Squibb
 2007-07 PHASE1
NCT01108705 Terminated
Carcinoma Hepatocellular
Bristol-Myers Squibb
 2010-05 Phase 3
NCT00355238 COMPLETED
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
 2006-12-31 PHASE2
NCT00390936 COMPLETED
Solid Tumors
Bristol-Myers Squibb
 2007-10 PHASE1
NCT01046864 Completed
Gastro-Intestinal Cancer
Bristol-Myers Squibb
 2010-02 Phase 1
NCT00858871 Completed
Hepato Cellular Carcinoma (HCC)
Bristol-Myers Squibb
 2009-05 Phase 3
NCT00207051 COMPLETED
Colorectal Cancer
Bristol-Myers Squibb
 2006-01 PHASE1
NCT00435669 COMPLETED
Tumors
Bristol-Myers Squibb
 2007-09 PHASE1
NCT00437437 COMPLETED
Tumors
Bristol-Myers Squibb
 2000-05 PHASE1
NCT00207103 COMPLETED
Tumors; Neoplasm Metastasis
Bristol-Myers Squibb
 2004-09 PHASE1

(data from https://clinicaltrials.gov, updated on 2024-07-23)

Check the Brivanib (BMS-540215) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Brivanib functions as an ATP-competitive inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) along with other VEGFR and fibroblast growth factor receptor (FGFR) family tyrosine kinases, blocking downstream receptor autophosphorylation and intracellular signaling pathways. This targeted inhibition selectively suppresses VEGF- and FGF-stimulated endothelial cell proliferation and tumor angiogenesis, providing therapeutic rationale for its investigation in clinical trials for advanced hepatocellular carcinoma and solid tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.